Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Is There a Continued Role for First-Generation TKIs in Resectable NSCLC?

January 17th 2022

Experts consider if there’s a role for the continued use of first-generation TKIs in patients with resected EGFR-positive non–small cell lung cancer.

The ADAURA Trial: Adjuvant Osimertinib in EGFR+ Resectable NSCLC

January 17th 2022

Shared insight on the clinical implications of the ADAURA trial, which tested osimertinib as adjuvant therapy following resection in patients with EGFR-positive NSCLC.

Optimized Treatment Starts With Molecular Testing in NSCLC

January 14th 2022

Konstantinos Arnaoutakis, MD, discusses new strategies in the management of ALK-positive non–small cell lung cancer, frontline immunotherapy, targeting EGFR, and biomarkers and targeted therapies in early-stage and advanced disease.

ADXS-503 Plus Pembrolizumab Shows Early Clinical Benefit, Safety in Metastatic NSCLC

January 13th 2022

The addition of ADXS-503 to the treatment of patients with metastatic non–small cell lung cancer who were progressing on pembrolizumab (Keytruda) resulted in encouraging responses and durable disease control, according to findings from the phase 1/2 trial.

ctDNA Testing Gains Ground in NSCLC With the Potential to Further Guide Treatment Decisions

January 12th 2022

Liquid biopsies are critical in understanding oncogenic drivers and resistance mechanisms in patients with non–small cell lung cancer.

Is There a Role for Postoperative Radiotherapy in Stage III NSCLC?

January 12th 2022

A brief discussion on the use of postoperative radiotherapy in non–small cell lung cancer following resection.

Treatment Strategies for Resectable NSCLC in Asia, With a Focus on Stage IB Disease

January 12th 2022

Perspectives on optimal treatment approaches for patients with resectable non–small cell lung cancer in Asia, with a focus on stage IB disease.

Case Review: Small Cell Lung Cancer Following LEMS

January 11th 2022

An oncologist reviews the case of a 57-year-old man diagnosed with small cell lung cancer after Lambert-Eaton myasthenic syndrome.

Monitoring Patients with SCLC and LEMS

January 11th 2022

Drs. Steven Vernino and David Gerber continue their conversation on their preferred treatment approaches and monitoring strategies for Lambert-Eaton myasthenic syndrome and small cell lung cancer.

Dr. Iams on Establishing the Clinical Utility of ctDNA Testing in Lung Cancer

January 10th 2022

Wade T. Iams, MD, discusses the need to establish the clinical utility of circulating tumor DNA testing in lung cancer.

NSCLC Paradigm Progresses With Adjuvant Treatment and Overcoming Resistance

January 10th 2022

As the armamentarium of advanced non–small cell lung cancer () continues to grow with the addition of novel targeted therapies for rare patient subtypes, the field is simultaneously shifting to evaluate targeted therapy and immunotherapy in earlier lines of treatment, including the neoadjuvant and adjuvant spaces.

Sotorasib Approved in Europe for KRAS G12C–Mutated Advanced NSCLC

January 10th 2022

The European Commission has granted conditional marketing authorization to sotorasib for the treatment of adult patients with KRAS G12C mutant advanced non–small cell lung cancer.

Adjuvant Pembrolizumab Improves DFS in Stage IB-IIIA NSCLC, Irrespective of PD-L1 Expression

January 10th 2022

Adjuvant treatment with pembrolizumab led to a statistically significant and clinically meaningful improvement in disease-free survival vs placebo in patients with stage IB to IIIA non–small cell lung cancer following resection, regardless of PD-L1 expression, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.

Future Outlook of EGFR Mutant NSCLC

January 10th 2022

Solange Peters, MD, PhD, and Tony SK Mok, MD, discuss what they’re looking forward to in the future for treating both stages of EGFR mutant NSCLC and give advice to colleagues treating this disease.

Updates in the Treatment of EGFR Mutant Advanced-Stage NSCLC

January 10th 2022

Drs Mok and Peters explain the updates seen in the treatment landscape for EGFR mutant advanced-stage NSCLC.

Immunotherapy Continues to Touch All Areas of Lung Cancer Treatment

January 9th 2022

David Spigel, MD, discussed the focus of each presentation, which centered on immunotherapy vs chemoimmunotherapy in the frontline metastatic setting, the surgical perspective of treatment in early-stage NSCLC, best practices for molecular testing, and EGFR- and KRAS-targeted therapies for patients with advanced disease.

Johnson Drives Home the Importance of Biomarker Testing in Lung Cancer

January 8th 2022

One of the reverberating themes of 2021 that should carry into 2022 is the importance of molecular testing.

Biomarkers for Guiding Treatment in NSCLC: Liquid Biopsy Versus Tissue-Based Testing

January 7th 2022

A comprehensive discussion on the value and limitations of tissue-based versus liquid-based biomarker testing in non–small cell lung cancer.

CLN-081 Continues to Elicit Encouraging, Durable Responses in EGFR Exon 20 Insertion+ NSCLC

January 6th 2022

CLN-081 continued to produce encouraging, durable responses with favorable safety and tolerability in patients with non–small cell lung cancer whose tumors harbor EGFR exon 20 insertion mutations and who have progressed on or after prior therapy.

A Gut Check on the Digital Divide: How Wearable Devices Are Changing Cancer Care

January 6th 2022

The idea to provide wearable devices to my patients first came to me 6 years ago at a charity spinning event.